311 related articles for article (PubMed ID: 30144374)
1. Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study.
Kuster S; Stampf S; Gerber B; Baettig V; Weisser M; Gerull S; Medinger M; Passweg J; Schanz U; Garzoni C; Berger C; Chalandon Y; Mueller NJ; van Delden C; Neofytos D; Khanna N;
Transpl Infect Dis; 2018 Dec; 20(6):e12981. PubMed ID: 30144374
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
3. Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study.
Harrison N; Mitterbauer M; Tobudic S; Kalhs P; Rabitsch W; Greinix H; Burgmann H; Willinger B; Presterl E; Forstner C
BMC Infect Dis; 2015 Dec; 15():584. PubMed ID: 26715563
[TBL] [Abstract][Full Text] [Related]
4. Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography.
Akahoshi Y; Kimura SI; Gomyo A; Hayakawa J; Tamaki M; Harada N; Kusuda M; Kameda K; Ugai T; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kikuchi M; Nakasone H; Kako S; Kanda Y
Infect Dis (Lond); 2018 Apr; 50(4):280-288. PubMed ID: 29087731
[TBL] [Abstract][Full Text] [Related]
5. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
[TBL] [Abstract][Full Text] [Related]
6. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center.
Lum L; Lee A; Vu M; Strasser S; Davis R
Transpl Infect Dis; 2020 Dec; 22(6):e13361. PubMed ID: 32510755
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
9. Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis.
Liu Q; Lin R; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Fan Z; Zhou H; Jiang Q; Zhang F; Zhai X; Xu D; Wei Y; Song J; Li Y; Feng R
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1198-203. PubMed ID: 24769013
[TBL] [Abstract][Full Text] [Related]
10. Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation.
Sun Y; Xu L; Liu D; Zhang X; Han W; Wang Y; Chen H; Chen Y; Wang F; Wang J; Ji Y; Tang F; Liu K; Huang XJ
Clin Microbiol Infect; 2013 Nov; 19(11):1029-34. PubMed ID: 23565830
[TBL] [Abstract][Full Text] [Related]
11. Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients.
Rodríguez-Veiga R; Montesinos P; García E; Boluda B; Rojas R; Serrano J; Martínez-Cuadrón D; Martín C; Sanz J; Tabares S; Piñana JL; Lorenzo I; Montoro J; Salavert M; Pemán J; Jarque I; Solves P; Sanz GF; Torres A; Sanz MA
Mycoses; 2019 May; 62(5):418-427. PubMed ID: 30633829
[TBL] [Abstract][Full Text] [Related]
12. A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
Sarina B; Mariotti J; Bramanti S; Morabito L; Crocchiolo R; Rimondo A; Tordato F; Pocaterra D; Casari E; De Philippis C; Carlo-Stella C; Santoro A; Castagna L
Transpl Infect Dis; 2018 Aug; 20(4):e12906. PubMed ID: 29668124
[TBL] [Abstract][Full Text] [Related]
13. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil.
Nucci M; Garnica M; Gloria AB; Lehugeur DS; Dias VC; Palma LC; Cappellano P; Fertrin KY; Carlesse F; Simões B; Bergamasco MD; Cunha CA; Seber A; Ribeiro MP; Queiroz-Telles F; Lee ML; Chauffaille ML; Silla L; de Souza CA; Colombo AL
Clin Microbiol Infect; 2013 Aug; 19(8):745-51. PubMed ID: 23009319
[TBL] [Abstract][Full Text] [Related]
14. Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients.
Piñana JL; Gómez MD; Montoro J; Lorenzo I; Pérez A; Giménez E; González-Barberá EM; Carretero C; Guerreiro M; Salavert M; Sanz G; Hernández-Boluda JC; Borrás R; Sanz J; Solano C; Navarro D
Transpl Infect Dis; 2019 Oct; 21(5):e13158. PubMed ID: 31402532
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
[TBL] [Abstract][Full Text] [Related]
16. Clinical performance of metagenomic next-generation sequencing for diagnosis of invasive fungal disease after hematopoietic cell transplant.
Zhang X; Zhang L; Li Y; Wang N; Zhang Y
Front Cell Infect Microbiol; 2024; 14():1210857. PubMed ID: 38590441
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring.
Yong MK; Ananda-Rajah M; Cameron PU; Morrissey CO; Spencer A; Ritchie D; Cheng AC; Lewin SR; Slavin M
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1961-1967. PubMed ID: 28797778
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of invasive fungal disease in haematologic patients.
Souza L; Nouér SA; Morales H; Simões B; Solza C; Queiroz-Telles F; Nucci M
Mycoses; 2021 Mar; 64(3):252-256. PubMed ID: 33141969
[TBL] [Abstract][Full Text] [Related]
19. Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study.
Ye P; Pei R; Hu Y; Chen D; Li S; Cao J; Li F; Wu M; Fang Y; Lu Y
BMC Infect Dis; 2022 May; 22(1):465. PubMed ID: 35570276
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
